Musculoskeletal Neoplasm

cancer family

Identifier: CI-CAN-00000278
Entity page: /cancer/musculoskeletal-neoplasm ↗
Edges: 1,217

Neighbours: 1 genes19 drugs10 trials
Drawn: 30 of 30 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Musculoskeletal Neoplasm approved for …APPROVED_FORderived6 of 6
← approved for	Leuprolideother FDA (US) · approved · 2020-05-01 · FENSOLVI ® is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). FENSOLVI is…	—	approved	Conventional Osteosarcoma	1	Regulatory	openfda	graph →
← approved for	Dactinomycin

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ALK Exon 2-18 Deletion Alectinib1 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ALK in this cancerno approval record in this cancercontext: Spindle Cell Rhabdomyosarcoma
PTPRD V253I Cixutumumab0 active / 5 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for PTPRD in this cancerno approval record in this cancercontext: Bone Ewing Sarcoma
PTPRD V253I Teprotumumab0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for PTPRD in this cancerno approval record in this cancercontext: Bone Ewing Sarcoma
TFCP2 Fusion Alectinib1 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for TFCP2 in this cancerno approval record in this cancercontext: Spindle Cell Rhabdomyosarcoma
CASP8 Overexpression Conatumumab0 active / 0 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for CASP8 in this cancerno approval record in this cancercontext: Bone Ewing Sarcoma
FGFR1 Amplification Ponatinib0 active / 0 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for FGFR1 in this cancerno approval record in this cancercontext: Bone Ewing Sarcoma
FOXO1 Fusion BET Inhibitor0 active / 0 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for FOXO1 in this cancerno approval record in this cancercontext: Alveolar Rhabdomyosarcoma
PDGFRA Overexpression Sunitinib0 active / 3 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for PDGFRA in this cancerno approval record in this cancercontext: Rhabdomyosarcoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Musculoskeletal Neoplasm altered in cohorts of …ALTERED_INderived1 of 1
← altered in cohorts of	MYOD1 20 / 20 cases (100 %) · ssm · soft_tissue_myod1_msk_2025	—	—	Rhabdomyosarcoma	1	Observed	cbioportal	graph →

Musculoskeletal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 122show all (up to 200)
→ investigated in trials for	Doxorubicinsmall molecule 32 trials (11 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 30 trials (16 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 24 trials (13 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 21 trials (9 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Ifosfamidesmall molecule 20 trials (5 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 17 trials (3 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 17 trials (10 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Dactinomycinother 13 trials (8 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 13 trials (2 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 13 trials (5 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Trabectedinsmall molecule 13 trials (4 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Denosumabmonoclonal antibody 12 trials (2 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 9 trials (1 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 9 trials (1 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 9 trials (1 active) · roll-up of the cancer and its descendants	—	—	Musculoskeletal Neoplasm	9	Observed	clinicaltrials	graph →

Musculoskeletal Neoplasm studied in …STUDIED_INderived10 of 1,088show all (up to 200)
→ studied in	NCT02923778Phase 2 · active not recruiting Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 1,088 trials mapped (303 active)	—	—	Leiomyosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03759717recruiting Molecular and Cellular Characterization of Skull Base Tumors · condition mapped ONTOLOGY_EXACT · 1,088 trials mapped (303 active)	—	—	Skull Base Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06308419Phase 1 · active not recruiting A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions · condition mapped ONTOLOGY_EXACT · 1,088 trials mapped (303 active)	—	—	Leiomyosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06441331Phase 1 · recruiting Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors · condition mapped ONTOLOGY_EXACT · 1,088 trials mapped (303 active)	—	—	Rhabdomyosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07193550Phase 2 · recruiting A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) · condition mapped ONTOLOGY_EXACT · 1,088 trials mapped (303 active)	—	—	Bone Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07508358Phase 1 · not yet recruiting Vaginal Sildenafil for Primary Dysmenorrhea · condition mapped ALIAS · 1,088 trials mapped (303 active)	—	—	Uterine Corpus Leiomyoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07839637completed Survey on Multiple Osteochondromas and Enchondromatoses During the Transition From Paediatric Care to Adult Care · condition mapped ALIAS · 1,088 trials mapped (303 active)	—	—	Multiple Osteochondromas	1	Observed	clinicaltrials	graph →
→ studied in	NCT04145518Phase 4 · completed Mechanistic Characterization of Uterine Pain · condition mapped ONTOLOGY_EXACT · 1,088 trials mapped (303 active)	—	—	Leiomyoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03210714Phase 2 · active not recruiting Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) · condition mapped CURATED_BROADER · 1,088 trials mapped (303 active)	—	—	Childhood Rhabdomyosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07830667Phase 1/Phase 2 · not yet recruiting A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat · condition mapped CURATED_BROADER · 1,088 trials mapped (303 active)	—	—	Childhood Rhabdomyosarcoma	1	Observed	clinicaltrials	graph →